Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.

Anti-cancer agents in medicinal chemistry - 1 Feb 2014

Leuci Valeria, Mesiano Giulia, Gammaitoni Loretta, Todorovic Maja, Giraudo Lidia, Carnevale-Schianca Fabrizio, Aglietta Massimo, Sangiolo Dario

Abstract excerpt

Adoptive immunotherapy is considered a promising strategy for the treatment of metastatic tumors and current research efforts are directed to define the optimal approach and facilitate the transferability from preclinical to clinical settings. Among several approaches it is possible to schematically distinguish strategies based on either MHC-restricted or MHC-unrestricted immune effectors. The first are mainly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Immunity, Innate

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunotherapy, Adoptive

Share to Killer Cells, Natural

Share to Major Histocompatibility Complex

Share to Natural Killer T-Cells

Share to Neoplasms

Share to Phenotype

Source

Identifiers

PMID: 24237224
DOI: 10.2174/18715206113136660371

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.PMID 24237224Read ↗

Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.Semantic proximity Read ↗

NKT cells - New players in CAR cell immunotherapy?Semantic proximity Read ↗

Chimeric antigen receptor-natural killer cell therapy: a new force in intrinsic immunotherapy for cancer treatmentSemantic proximity Read ↗

Cytotoxic CD8+ T cells in cancer and cancer immunotherapySemantic proximity Read ↗

Chimeric antigen receptor-natural killer cell therapy: current advancements and strategies to overcome challengesSemantic proximity Read ↗

A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?Semantic proximity Read ↗

Advantages and clinical applications of natural killer cells in cancer immunotherapy.Semantic proximity Read ↗

Natural killer cell‐based immunotherapy in cancer: current insights and future prospectsSemantic proximity Read ↗

Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy.Semantic proximity Read ↗

The Role of Natural Killer T Cells in Cancer—A Phenotypical and Functional ApproachSemantic proximity Read ↗

Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.Semantic proximity Read ↗

CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor VaccineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.